- Home
- NURO vs CANF Comparison
NURO vs CANF Comparison
Compare NURO & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NURO
- CANF
- Stock Information
- Founded
- NURO 1996
- CANF 1994
- Country
- NURO United States
- CANF Israel
- Employees
- NURO N/A
- CANF N/A
- Industry
- NURO Medical/Dental Instruments
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- NURO Health Care
- CANF Health Care
- Exchange
- NURO Nasdaq
- CANF Nasdaq
- Market Cap
- NURO N/A
- CANF 7.9M
- IPO Year
- NURO N/A
- CANF N/A
- Fundamental
- Price
- NURO $4.36
- CANF $1.09
- Analyst Decision
- NURO
- CANF Strong Buy
- Analyst Count
- NURO 0
- CANF 2
- Target Price
- NURO N/A
- CANF $14.00
- AVG Volume (30 Days)
- NURO 3.5K
- CANF 422.0K
- Earning Date
- NURO 05-14-2025
- CANF 05-13-2025
- Dividend Yield
- NURO N/A
- CANF N/A
- EPS Growth
- NURO N/A
- CANF N/A
- EPS
- NURO N/A
- CANF N/A
- Revenue
- NURO $3,032,837.00
- CANF $674,000.00
- Revenue This Year
- NURO N/A
- CANF $461.72
- Revenue Next Year
- NURO N/A
- CANF N/A
- P/E Ratio
- NURO N/A
- CANF N/A
- Revenue Growth
- NURO N/A
- CANF N/A
- 52 Week Low
- NURO $2.66
- CANF $1.22
- 52 Week High
- NURO $4.73
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- NURO 47.71
- CANF 34.28
- Support Level
- NURO $4.28
- CANF $1.13
- Resistance Level
- NURO $4.45
- CANF $1.19
- Average True Range (ATR)
- NURO 0.06
- CANF 0.11
- MACD
- NURO -0.00
- CANF -0.02
- Stochastic Oscillator
- NURO 52.63
- CANF 1.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).